Brand & Product Security

Articles

White House announces official endorsement, paving way for Senate confirmation process


Califf nominated to head FDA

It’s not just innovator pharma companies concerned with the proposed compromise to Medicare price negotiations and inflation-based rebates

Generic drugmakers also fight price controls

Respondents: Pharmacies are still lagging in the compliance requirements that will be in effect in November 2023

The pace of DSCSA readiness preparations has slowed, says annual HDA survey

As companies seek interoperability across their organizations, a joint approach to
medical information and local pharmacovigilance may deliver future benefits

Aligning Medical Information and PV

Exploring new guidances and future challenges for pharma trading partners in meeting looming DSCSA mandates in the US 

2023 challenges of the Drug Supply Chain Security Act implementation on wholesale drug distributors 

Michael Christel is Group Managing Editor of Pharmaceutical Commerce, Pharmaceutical Executive, and Applied Clinical Trials. He can be reached at mchristel@mjhlifesciences.com.

The pandemic has accelerated the adoption of enterprise resource planning in pharma supply chain management, as the recent US rise of one “technology enabler” attests    

ERP for pharma: When growth and need collide

A dramatic shift to e-sampling has been the effective counter to the reduced number of rep visits to physicians’ offices

Preserving Drug Sampling Activity

Recent FDA actions may finally usher in access boost to follow-on biologics in the US 

Biosimilars gain traction with regulators, manufacturers

FDA’s recommended guidance is for a system that ‘does not exist, cannot be built by 2023, and poses unacceptable security and compliance risks,’ says alliance

HDA calls for withdrawal of FDA’s latest DSCSA guidance on the ‘enhanced drug distribution system’

Plan aims to offset costs associated with proposed social and health initiatives  

Legal & Regulatory